|
In 1996, the Michigan legislature passed a historic law that set reasonable limits on lawsuits against makers of FDA-approved drugs, with the express purpose of triggering investment in the state’s life-sciences industries. Now, the litigation industry is trying to overturn this model reform, putting Michigan’s thriving medical sector in danger and jeopardizing research on medicine our families need.
The Manhattan Institute’s Center for Legal Policy has released an excellent report on the efforts of the plaintiff’s bar to repeal Michigan’s FDA defense law. The report is entitled: Trial Lawyers, Inc. Update: The Move to Reverse Michigan’s Model Reforms.
Click here to read this important report.
Trial Lawyers, Inc. Update: The Move to Reverse Michigan’s Model Reforms aims to:
- Debunk the myth that the trial bar’s aim is to protect public health and “the little guy”
- Assess the threat to Michigan’s economy posed by a litigious business climate
- Highlight Michigan’s unique FDA defense law as a model for nationwide reform efforts
|
